Zymeworks Inc. - ZYME
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 13, 2026 | SCHEDULE 13G/A | Rubric Capital Management LP | 7.68% | 5,750,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Rosen | 7.68% | 5,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Morgan Stanley | 3.4% | 2,519,243 | View |
| Nov 19, 2025 | SCHEDULE 13D/A | — | 30.7% | — | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.7% | 2,045,162 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 2.7% | 2,045,162 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.1% | 1,601,489 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 2.1% | 1,601,489 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.3% | 212,898 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.3% | 212,898 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 4.9% | 3,646,651 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 5.2% | 3,938,641 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF INC/IL | 5.2% | 3,938,641 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 5.2% | 3,938,641 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Redmile Group, LLC | 4.9% | 3,705,750 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Jeremy C. Green | 4.9% | 3,705,750 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.